ArticleMolecular cancer therapeutics2025

Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Niki M Zacharias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.